Aviva Bio is a clinical-stage biotechnology company unlocking the full potential of hormone-based medicine. Through novel drug design and a focus on unmet needs in women’s health, Aviva Bio is developing first-in-class therapeutics to improve lives. Its lead program, AVA-291 (d3-Testosterone), is on track to become the first FDA-approved testosterone therapy designed for women.
Company Details
- Employees
- 3
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://aviva-bio.com/
- Keywords
- Ocular Therapeutix.
Aviva Bio Questions
Aviva Bio's website is https://aviva-bio.com/
Aviva Bio's LinkedIn profile is https://www.linkedin.com/company/aviva-bio
Aviva Bio has
3 employees.
View email and phone details for 3
employees at Aviva Bio.
Aviva Bio's industry is
Biotechnology Research
Aviva Bio's top competitors are
Vala Sciences,
Eyepoint,
Ocular Therapeutix, Inc.,
Aviva Biosciences,
Lennham Pharmaceuticals,
Brainxell,
D9 Designs Inc.,
Tremeau Pharmaceuticals, Inc.,
Rezolute, Inc.,
Hls Therapeutics Inc..
Aviva Bio's categories are Biotechnology Research
Aviva Bio's founding year is 2025
